[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Belite Bio Inc ADR (BLTE)

Belite Bio Inc ADR (BLTE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,189,780
  • Shares Outstanding, K 39,965
  • Annual Sales, $ 0 K
  • Annual Income, $ -77,610 K
  • EBIT $ -84 M
  • EBITDA $ -84 M
  • 60-Month Beta -1.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.59
  • Number of Estimates 4
  • High Estimate $-0.48
  • Low Estimate $-0.70
  • Prior Year $-0.45
  • Growth Rate Est. (year over year) -31.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
147.84 +4.76%
on 05/07/26
183.67 -15.67%
on 04/09/26
-23.85 (-13.34%)
since 04/08/26
3-Month
146.61 +5.64%
on 03/24/26
192.28 -19.45%
on 02/27/26
-32.98 (-17.56%)
since 02/06/26
52-Week
56.10 +176.08%
on 07/02/25
200.00 -22.56%
on 02/03/26
+93.95 (+154.19%)
since 05/08/25

Most Recent Stories

More News
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc. (NASDAQ: BLTE), (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing...

BLTE : 154.88 (-0.72%)
Belite Bio to Participate in Four Upcoming Investor Conferences

SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 154.88 (-0.72%)
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease

Belite expects to complete the new drug application submission in the second quarter of 2026 Rolling submission initiated under Breakthrough Therapy Designation SAN DIEGO, April 21, 2026 (GLOBE...

BLTE : 154.88 (-0.72%)
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that...

BLTE : 154.88 (-0.72%)
Belite Bio to Participate in the Leerink Global Healthcare Conference

SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc  (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 154.88 (-0.72%)
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), the Company is on track to submit a New Drug Application...

BLTE : 154.88 (-0.72%)
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases...

BLTE : 154.88 (-0.72%)
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 154.88 (-0.72%)
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint in the pivotal, global Phase 3 DRAGON trial with 36% reduction in lesion...

BLTE : 154.88 (-0.72%)
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 154.88 (-0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Belite Bio Inc. is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease, and metabolic diseases....

See More

Key Turning Points

3rd Resistance Point 161.53
2nd Resistance Point 159.26
1st Resistance Point 157.07
Last Price 154.88
1st Support Level 152.61
2nd Support Level 150.34
3rd Support Level 148.15

See More

52-Week High 200.00
Last Price 154.88
Fibonacci 61.8% 145.03
Fibonacci 50% 128.05
Fibonacci 38.2% 111.07
52-Week Low 56.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.